T1	CHEM 331 341	BMS-936558
#1	AnnotatorNotes T1	C4552119; BMS-936558; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T2	PROC 87 98	tratamiento
#2	AnnotatorNotes T2	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T3	CHEM 133 144	dacarbazina
#3	AnnotatorNotes T3	C0010927; dacarbazine; Organic Chemical · Pharmacologic Substance
T4	CHEM 147 159	carboplatino
#4	AnnotatorNotes T4	C0079083; carboplatin; Organic Chemical · Pharmacologic Substance
T5	CHEM 162 172	paclitaxel
#5	AnnotatorNotes T5	C0144576; paclitaxel; Organic Chemical · Pharmacologic Substance
T6	DISO 190 198	melanoma
#6	AnnotatorNotes T6	C0025202; melanoma; Neoplastic Process
T7	PROC 240 251	tratamiento
#7	AnnotatorNotes T7	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T8	CHEM 256 267	anti-CTLA-4
T9	PROC 290 326	Ensayo fase 3, aleatorizado, abierto
T10	PROC 352 363	tratamiento
#8	AnnotatorNotes T10	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T11	DISO 409 417	melanoma
#9	AnnotatorNotes T11	C0025202; melanoma; Neoplastic Process
T12	PROC 480 491	tratamiento
#10	AnnotatorNotes T12	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T13	CHEM 496 507	anti-CTLA-4
T14	DISO 586 594	melanoma
#11	AnnotatorNotes T14	C0025202; melanoma; Neoplastic Process
T15	DISO 718 726	Melanoma
#12	AnnotatorNotes T15	C0025202; melanoma; Neoplastic Process
T16	ANAT 1293 1300	muestra
#13	AnnotatorNotes T16	C2347026; Biospecimen; Body Substance
T17	DISO 803 821	Enfermedad medible
#14	AnnotatorNotes T17	C1513041; Measurable Disease; Disease or Syndrome
T18	PROC 1421 1442	estudios correlativos
#15	AnnotatorNotes T18	C1511524; Correlative Study; Research Activity
T19	PROC 836 838	RM
#16	AnnotatorNotes T19	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T20	DISO 912 939	progresión de la enfermedad
#17	AnnotatorNotes T20	C0242656; Disease Progression; Pathologic Function
T21	DISO 1072 1080	melanoma
#18	AnnotatorNotes T21	C0025202; melanoma; Neoplastic Process
T22	PROC 1094 1109	Pre-tratamiento
T23	PROC 1134 1149	biopsia tumoral
T24	DISO 1142 1149	tumoral
#19	AnnotatorNotes T24	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C0577559; Mass of body structure; Finding
T25	CHEM 1254 1260	formol
#20	AnnotatorNotes T25	C0016584; Formol; Organic Chemical · Hazardous or Poisonous Substance | C0949307; formalin; Organic Chemical · Pharmacologic Substance · Hazardous or Poisonous Substance
T26	PROC 1285 1289	FFIP
#21	AnnotatorNotes T26	C4684951; Formalin-Fixed Paraffin-Embedded; Laboratory Procedure
T27	CHEM 1275 1283	parafina
#22	AnnotatorNotes T27	C0030415; paraffin; Organic Chemical · Pharmacologic Substance
T28	PROC 1352 1365	preparaciones
#23	AnnotatorNotes T28	C0200363; Specimen preparation; Laboratory Procedure
T29	PROC 1369 1376	teñidas
T30	PROC 1483 1494	tratamiento
#24	AnnotatorNotes T30	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T31	PROC 1501 1515	ensayo clínico
#25	AnnotatorNotes T31	C0008976; Clinical Trials; Research Activity
T32	CHEM 1520 1530	BMS-936558
#26	AnnotatorNotes T32	C4552119; BMS-936558; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T33	PROC 1571 1613	tratamiento sistémico con corticosteroides
T34	CHEM 1597 1613	corticosteroides
#27	AnnotatorNotes T34	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T35	CHEM 1626 1636	prednisona
#28	AnnotatorNotes T35	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T36	CHEM 1667 1696	medicamentos inmunosupresores
T37	CHEM 1751 1758	fármaco
#29	AnnotatorNotes T37	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T38	CHEM 1788 1798	esteroides
#30	AnnotatorNotes T38	C0038317; Steroids; Organic Chemical · Pharmacologic Substance
T39	CHEM 1830 1840	esteroides
#31	AnnotatorNotes T39	C0038317; Steroids; Organic Chemical · Pharmacologic Substance
T40	ANAT 1856 1867	suprarrenal
#32	AnnotatorNotes T40	C0001625; Adrenal Glands; Body Part, Organ, or Organ Component
T41	CHEM 1879 1889	prednisona
#33	AnnotatorNotes T41	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T42	DISO 1927 1948	enfermedad autoinmune
#34	AnnotatorNotes T42	C0004364; Autoimmune Diseases; Disease or Syndrome
T43	DISO 1960 1981	Enfermedad autoinmune
#35	AnnotatorNotes T43	C0004364; Autoimmune Diseases; Disease or Syndrome
T44	DISO 2028 2036	melanoma
#36	AnnotatorNotes T44	C0025202; melanoma; Neoplastic Process
T45	DISO 2077 2098	Metástasis cerebrales
#37	AnnotatorNotes T45	C0220650; Metastatic malignant neoplasm to brain; Neoplastic Process | C0555278; Cerebral metastasis; Neoplastic Process
T46	DISO 2109 2134	metástasis leptomeníngeas
#38	AnnotatorNotes T46	C1704231; Metastatic Malignant Neoplasm to the Leptomeninges; Neoplastic Process
T47	DISO 2139 2154	Melanoma ocular
#39	AnnotatorNotes T47	C0558356; Malignant melanoma of eye; Neoplastic Process
T48	PROC 2182 2193	tratamiento
#40	AnnotatorNotes T48	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T49	CHEM 2205 2214	anti-PD-1
T50	CHEM 2216 2226	anti-PD-L1
T51	CHEM 2229 2239	anti PD L2
T52	DISO 442 453	metastásico
#41	AnnotatorNotes T52	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T53	DISO 609 620	metastásico
#42	AnnotatorNotes T53	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T54	PROC 831 833	TC
#43	AnnotatorNotes T54	C0040405; X-Ray Computed Tomography; Diagnostic Procedure
T55	PROC 1034 1058	regímenes de tratamiento
T56	PROC 1125 1133	escisión
#44	AnnotatorNotes T56	C0728940; Excision; Therapeutic or Preventive Procedure
T57	PROC 1178 1192	consentimiento
#45	AnnotatorNotes T57	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T58	PROC 1732 1758	administración del fármaco
#46	AnnotatorNotes T58	C3469597; Administration of medication; Therapeutic or Preventive Procedure
T59	ANAT 2088 2098	cerebrales
#47	AnnotatorNotes T59	C0242202; Cerebrum; Body Part, Organ, or Organ Component | C1269537; Entire brain; Body Part, Organ, or Organ Component | C1280654; Entire cerebrum; Body Part, Organ, or Organ Component
T60	ANAT 2120 2134	leptomeníngeas
#48	AnnotatorNotes T60	C0228126; Leptomeninges; Body Part, Organ, or Organ Component | C1284563; Entire leptomeninges; Body Part, Organ, or Organ Component
T61	ANAT 2148 2154	ocular
#49	AnnotatorNotes T61	C0015392; Eye; Body Part, Organ, or Organ Component | C1280202; Entire eye; Body Part, Organ, or Organ Component
T62	CHEM 66 76	BMS-936558
#50	AnnotatorNotes T62	C4552119; BMS-936558; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T63	Date 12 16	2012
T64	LIVB 114 126	investigador
#51	AnnotatorNotes T64	C0035173; Research Personnel; Professional or Occupational Group
T65	LIVB 176 185	pacientes
#52	AnnotatorNotes T65	C0030705; Patients; Patient or Disabled Group
T66	LIVB 379 391	investigador
#53	AnnotatorNotes T66	C0035173; Research Personnel; Professional or Occupational Group
T67	LIVB 395 404	pacientes
#54	AnnotatorNotes T67	C0030705; Patients; Patient or Disabled Group
T68	Date 541 563	el 24 de abril de 2014
T69	LIVB 660 667	mujeres
#55	AnnotatorNotes T69	C0043210; Woman; Population Group
T72	LIVB 878 885	sujetos
#56	AnnotatorNotes T72	C0681850; Study Subject; Group
T74	LIVB 1157 1164	sujetos
#57	AnnotatorNotes T74	C0681850; Study Subject; Group
T75	Neg_cue 1366 1368	no
T77	LIVB 1535 1542	Sujetos
#58	AnnotatorNotes T77	C0681850; Study Subject; Group
T78	Dose 1615 1622	> 10 mg
T79	Frequency 1637 1643	al día
T80	Duration 1712 1719	14 días
T81	Route 1799 1808	inhalados
#59	AnnotatorNotes T81	C0205535; Inhalation Route of Drug Administration; Functional Concept
T82	Route 1811 1818	tópicos
#60	AnnotatorNotes T82	C1522168; Topical Route of Drug Administration; Functional Concept
T83	Dose 1868 1875	> 10 mg
T84	Frequency 1890 1896	diaria
T85	Neg_cue 1915 1926	ausencia de
T86	Spec_cue 2001 2011	sospechada
T87	LIVB 2015 2022	Sujetos
#61	AnnotatorNotes T87	C0681850; Study Subject; Group
T88	LIVB 2159 2166	Sujetos
#62	AnnotatorNotes T88	C0681850; Study Subject; Group
T90	Age 668 680	≥ 18 de años
T91	LIVB 650 657	Varones
#63	AnnotatorNotes T91	C0025266; Male population group; Population Group
T70	GENE 2056 2060	BRAF
#64	AnnotatorNotes T70	C0812241; BRAF gene; Gene or Genome
T71	PROC 684 700	Estado funcional
#65	AnnotatorNotes T71	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T73	PROC 783 799	histológicamente
#66	AnnotatorNotes T73	C0344441; Histology Procedure; Laboratory Procedure
T76	PROC 1322 1333	histológico
#67	AnnotatorNotes T76	C0344441; Histology Procedure; Laboratory Procedure
A1	Assertion T29 Negated
A2	Assertion T42 Negated
A3	Assertion T43 Speculated
A4	Status T43 History_of
A5	Status T48 History_of
A6	Status T49 History_of
A7	Status T50 History_of
A8	Status T51 History_of
A9	Status T55 History_of
#68	AnnotatorNotes T9	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C1709323; Open Label Study; Research Activity 
#69	AnnotatorNotes T33	C4053960; Systemic Corticosteroid Therapy; Therapeutic or Preventive Procedure
#70	AnnotatorNotes T36	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
#71	AnnotatorNotes T49	C4289971; Anti-PD-L1 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#72	AnnotatorNotes T50	C4289971; Anti-PD-L1 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#73	AnnotatorNotes T13	C4289973; Anti-CTLA-4 Monoclonal Antibody; Amino Acid, Peptide, or Protein
#74	AnnotatorNotes T8	C4289973; Anti-CTLA-4 Monoclonal Antibody; Amino Acid, Peptide, or Protein
T89	Observation 2046 2060	estado de BRAF
A10	Assertion T89 Speculated
T92	Spec_cue 2061 2072	desconocido
R1	Speculation Arg1:T92 Arg2:T89	
T93	Quantifier_or_Qualifier 1949 1955	activa
A11	Assertion T93 Negated
#75	AnnotatorNotes T93	C0679217; Active State; Idea or Concept
R2	Has_Quantifier_or_Qualifier Arg1:T42 Arg2:T93	
R3	Negation Arg1:T85 Arg2:T42	
R4	Negation Arg1:T85 Arg2:T93	
R5	Used_for Arg1:T3 Arg2:T2	
R6	Used_for Arg1:T4 Arg2:T2	
R7	Combined_with Arg1:T4 Arg2:T5	
R8	Experiences Arg1:T65 Arg2:T62	
R9	Experiences Arg1:T65 Arg2:T2	
R10	Experiences Arg1:T65 Arg2:T3	
R11	Experiences Arg1:T65 Arg2:T4	
R12	Experiences Arg1:T65 Arg2:T6	
R13	Used_for Arg1:T8 Arg2:T7	
R14	Experiences Arg1:T65 Arg2:T7	
R15	Before Arg1:T7 Arg2:T62	
R16	Before Arg1:T7 Arg2:T3	
R17	Before Arg1:T7 Arg2:T2	
R18	Before Arg1:T7 Arg2:T4	
T94	Quantifier_or_Qualifier 199 207	avanzado
#76	AnnotatorNotes T94	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R19	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T94	
T95	Quantifier_or_Qualifier 418 426	avanzado
#77	AnnotatorNotes T95	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R20	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T95	
T96	Quantifier_or_Qualifier 1081 1089	avanzado
#78	AnnotatorNotes T96	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R21	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T96	
R22	Experiences Arg1:T67 Arg2:T1	
R23	Experiences Arg1:T67 Arg2:T10	
R24	Experiences Arg1:T67 Arg2:T11	
R25	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T52	
R26	Used_for Arg1:T13 Arg2:T12	
R27	Experiences Arg1:T67 Arg2:T52	
R28	Experiences Arg1:T67 Arg2:T12	
R29	Before Arg1:T12 Arg2:T1	
R30	Before Arg1:T12 Arg2:T10	
T97	Observation 455 468	en progresión
#79	AnnotatorNotes T97	C1457868; Worse; Finding (?)
R31	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T97	
R32	After Arg1:T97 Arg2:T12	
T98	Observation 218 228	progresado
#80	AnnotatorNotes T98	C1457868; Worse; Finding (?)
R33	Before Arg1:T6 Arg2:T98	
R34	After Arg1:T98 Arg2:T7	
T99	Observation 595 606	irresecable
#81	AnnotatorNotes T99	C4039777; Tumor surgically unresectable; Finding
R35	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T99	
R36	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T53	
R37	Experiences Arg1:T67 Arg2:T97	
T100	Observation 428 439	irresecable
#82	AnnotatorNotes T100	C4039777; Tumor surgically unresectable; Finding
R38	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T100	
R39	Has_Age Arg1:T91 Arg2:T90	
R40	Has_Age Arg1:T69 Arg2:T90	
T101	CONC 702 706	ECOG
#83	AnnotatorNotes T101	C1520224; ECOG performance status; Intellectual Product
T102	Result_or_Value 711 714	0-1
R41	Has_Result_or_Value Arg1:T101 Arg2:T102	
R42	Used_for Arg1:T101 Arg2:T71	
T103	Quantifier_or_Qualifier 730 741	estadio III
T104	Quantifier_or_Qualifier 761 771	estadio IV
R44	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T103	
R45	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T104	
T105	Observation 743 754	irresecable
#84	AnnotatorNotes T105	C4039777; Tumor surgically unresectable; Finding
R46	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T105	
T106	CONC 849 869	criterios RECIST 1.1
#85	AnnotatorNotes T106	C1709926; Response Evaluation Criteria in Solid Tumors; Intellectual Product
R50	Experiences Arg1:T72 Arg2:T20	
T107	CONC 977 993	criterios RECIST
#86	AnnotatorNotes T107	C1709926; Response Evaluation Criteria in Solid Tumors; Intellectual Product
R51	After Arg1:T20 Arg2:T55	
R52	Overlap Arg1:T20 Arg2:T55	
T108	Quantifier_or_Qualifier 1015 1033	1 y como máximo, 2
R53	Has_Quantifier_or_Qualifier Arg1:T55 Arg2:T108	
R54	Before Arg1:T21 Arg2:T20	
R55	Experiences Arg1:T72 Arg2:T55	
R56	Experiences Arg1:T72 Arg2:T21	
T109	Quantifier_or_Qualifier 1117 1122	nuevo
#87	AnnotatorNotes T109	C0205314; New; Qualitative Concept
R57	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T109	
R60	Before Arg1:T57 Arg2:T26	
T110	Quantifier_or_Qualifier 1301 1311	de archivo
#88	AnnotatorNotes T110	C4724030; Archived; Functional Concept
R61	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T110	
R62	Location_of Arg1:T60 Arg2:T46	
R63	Location_of Arg1:T59 Arg2:T45	
R64	Location_of Arg1:T61 Arg2:T47	
R65	Experiences Arg1:T88 Arg2:T48	
R66	Used_for Arg1:T49 Arg2:T48	
R67	Used_for Arg1:T50 Arg2:T48	
R68	Used_for Arg1:T51 Arg2:T48	
R69	Experiences Arg1:T87 Arg2:T44	
R70	Overlap Arg1:T44 Arg2:T89	
R71	Speculation Arg1:T86 Arg2:T43	
T111	Quantifier_or_Qualifier 1982 1988	activa
#89	AnnotatorNotes T111	C0679217; Active State; Idea or Concept
R72	Has_Quantifier_or_Qualifier Arg1:T43 Arg2:T111	
T112	Quantifier_or_Qualifier 2099 2106	activas
#90	AnnotatorNotes T112	C0679217; Active State; Idea or Concept
R73	Has_Quantifier_or_Qualifier Arg1:T45 Arg2:T112	
R74	Used_for Arg1:T32 Arg2:T30	
T113	Quantifier_or_Qualifier 1336 1351	un mínimo de 10
R75	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T113	
R76	Negation Arg1:T75 Arg2:T29	
#91	AnnotatorNotes T29	C0487602; Staining method; Laboratory Procedure
R77	Before Arg1:T26 Arg2:T18	
R78	Before Arg1:T28 Arg2:T18	
R79	Before Arg1:T29 Arg2:T18	
R80	Experiences Arg1:T74 Arg2:T76	
R81	Experiences Arg1:T74 Arg2:T28	
R82	Before Arg1:T57 Arg2:T76	
R83	Before Arg1:T57 Arg2:T28	
R84	Before Arg1:T57 Arg2:T29	
R85	Experiences Arg1:T77 Arg2:T33	
R86	Used_for Arg1:T34 Arg2:T33	
R87	Used_for Arg1:T35 Arg2:T33	
R88	Has_Dose_or_Strength Arg1:T35 Arg2:T78	
R89	Has_Frequency Arg1:T35 Arg2:T79	
T114	CONC 1623 1636;1646 1657	de prednisona equivalente
R90	Experiences Arg1:T77 Arg2:T36	
R91	Overlap Arg1:T34 Arg2:T80	
R92	Overlap Arg1:T36 Arg2:T80	
R93	Overlap Arg1:T35 Arg2:T80	
R94	Before Arg1:T33 Arg2:T58	
R95	Before Arg1:T35 Arg2:T58	
R96	Before Arg1:T36 Arg2:T58	
R97	Used_for Arg1:T37 Arg2:T58	
R98	Experiences Arg1:T77 Arg2:T58	
T115	PROC 1244 1283	fijado en formol e incluido en parafina
#92	AnnotatorNotes T115	C4684951; Formalin-Fixed Paraffin-Embedded; Laboratory Procedure
R99	Before Arg1:T57 Arg2:T115	
R100	Has_Route_or_Mode Arg1:T38 Arg2:T81	
R101	Has_Route_or_Mode Arg1:T38 Arg2:T82	
T116	CONC 1772 1783	Se permiten
R102	Has_Frequency Arg1:T41 Arg2:T84	
R103	Has_Dose_or_Strength Arg1:T41 Arg2:T83	
R104	Has_Dose_or_Strength Arg1:T39 Arg2:T83	
R105	Has_Frequency Arg1:T39 Arg2:T84	
#93	AnnotatorNotes T23	C0184924; Punch biopsy (procedure); Diagnostic Procedure 
#94	AnnotatorNotes T55	C1276413; Therapeutic regimen; Therapeutic or Preventive Procedure
A12	Experiencer T77 Patient
A13	Experiencer T64 Other
A14	Experiencer T65 Patient
A15	Experiencer T66 Other
A16	Experiencer T67 Patient
A17	Experiencer T69 Patient
A18	Experiencer T91 Patient
A19	Experiencer T72 Patient
A20	Experiencer T74 Patient
A21	Experiencer T87 Patient
A22	Experiencer T88 Patient
